



1 Fee #

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/827,428-Conf. #6098	
	Filing Date	April 6, 2001	
	First Named Inventor	Seth J. ORLOW	
	Art Unit	1614	
	Examiner Name	A. A. Lewis	
Total Number of Pages in This Submission	6	Attorney Docket Number	0071369.00162US3/PFI-016CIP

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature			
Printed name	Ann-Louise Kerner, Ph.D.		
Date	December 7, 2006	Reg. No.	33,523

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: December 7, 2006	Signature: (Stephanie R. Douglas)

6



PTO/SB/17 (07-06)
Approved for use through 01/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.


FEE TRANSMITTAL For FY 2006		Complete if Known		
		Application Number	09/827,428-Conf. #6098	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date	April 6, 2001	
		First Named Inventor	Seth J. ORLOW	
		Examiner Name	A. A. Lewis	
TOTAL AMOUNT OF PAYMENT (\$)		180.00	Attorney Docket No.	0071369.00162US3/PFI-016CIP

METHOD OF PAYMENT (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 08-0219
Deposit Account Name: Wilmer Cutler Pickering Hale and Dorr LLP	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		Small Entity		Small Entity		Small Entity	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
						Small Entity	
						Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
- =		x	=		Fee (\$)		Fee Paid (\$)
HIP = highest number of total claims paid for, if greater than 20.							
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
- =		x	=				
HIP = highest number of independent claims paid for, if greater than 3.							
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets		Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)	
- 100 =		/50	(round up to a whole number) x		=		
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)							
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement						180.00	

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	33,523
Name (Print/Type)	Ann-Louise Kerner, Ph.D.	Telephone	(617) 526-6000
		Date	December 7, 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: December 7, 2006	Signature: Stephanie R. Douglas)



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: December 7, 2006

Signature:

Stephanie R. Douglas
(Stephanie R. Douglas)

Docket No.: 0071369.00162US3/PFI-016CIP
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Seth J. ORLOW et al. Confirmation No.: 6098
Application No.: 09/827,428 Art Unit: 1614
Filed: April 6, 2001 Examiner: A. A. Lewis
Title: METHODS AND COMPOSITIONS THAT AFFECT
MELANOGENESIS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: December 7, 2006

Ann-Louise Kerner

Ann-Louise Kerner, Ph.D.
Registration No.: 33,523
Attorney for Applicant(s)


Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000 (telephone)
(617) 526-5000 (facsimile)

US1DOCS 5968254v1

12/12/2006 EAREGAY1 00000033 080219 09827428

01 FC:1806

180.00 DA



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/827,428-Conf. #6098		
		Filing Date	April 6, 2001		
		First Named Inventor	Seth J. ORLOW		
		Art Unit	1614		
		Examiner Name	A. A. Lewis		
Sheet	1	of	3	Attorney Docket Number	0071369.00162US3/PFI-016CIP


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-5,628,987	05-13-1997	Fuller	
	AB*	US-5,686,103	11-11-1997	Redziniak et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-01/01131	01-04-2001	Univ New York		
	BB	WO-97/00892	01-09-1997	Us Health et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	ABDEL-MALEK, et al., "Mitogenic, Melanogenic and cAMP Responses of Cultured Neonatal Human Melanocytes to Commonly Used Mitogens", Journal of Cellular Physiology, 150:416-425 (1992)		
	CB	ANCANS, et al., "Activation of Melanogenesis by Vacuolar Type H ⁺ -ATPase Inhibitors in Amelanotic, Tyrosinase Positive Human and Mouse Melanoma Cells", FEBS Letters, 478:57-60 (2000)		
	CC	ANSEL, et al., <u>Pharmaceutical Dosage Forms and Drug Delivery Systems</u> , Sixth Ed., A Lea & Febiger Book, Williams & Wilkins, Baltimore (1995)		
	CD	BOUCHARD, et al., "Induction of Pigmentation in Mouse Fibroblasts by Expression of Human Tyrosinase cDNA", J. Exp. Med., 169:2029-2042 (1989)		
	CE	BRILLIANT, et al., "Anatomy of Pigment Cell Genes Acting at the Cellular Lever", in <u>The Pigmentary System: Physiology and Pathophysiology</u> , Norlund, et al., eds., Oxford University Press, Chapter 18, pp. 217-229 (1998)		
	CF	CHAKRABORTY, et al., "Effect of Arbutin on Melanogenic Proteins in Human Melanocytes", Pigment Cell Research, 11:206-212 (1998)		
	CG	GARDNER, et al., "The Complete Nucleotide Sequence of an Infectious Clone of Cauliflower Mosaic Virus by M13mp7 Shotgun Sequencing", Nucleic Acids Research, 9(12):2871-2888 (1981)		
	CH	GILBERT, et al., "Useful Proteins from Recombinant Bacteria", Sci. Am., 242(4):74-94 (1980)		
	CI	HALL, et al., "Accumulation of Tyrosinase in the Endolysosomal Compartment in Induced by U18666A", Pigment Cell Res., 16:149-158 (2003)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/827,428-Conf. #6098
				Filing Date	April 6, 2001
				First Named Inventor	Seth J. ORLOW
				Art Unit	1614
				Examiner Name	A. A. Lewis
Sheet	2	of	3	Attorney Docket Number	0071369.00162US3/PFI-016CIP

CJ	HARLOW, et al., <u>Antibodies - A Laboratory Manual</u> , Cold Spring Harbor Laboratory (1988) (cover of book and page (i))	
CK	HU, et al., "Regulation of Melanogenesis by Human Uveal Melanocytes In Vitro", <u>Exp. Eye Res.</u> , 64:397-404 (1997)	
CL	IMOKAWA, et al., "Skin Organ Culture Model for Examining Epidermal Melanization", <u>Journal of Investigative Dermatology</u> , 100:47-54 (1993)	
CM	JIMENEZ, et al., "Tyrosinases from Two Different Loci are Expressed by Normal and by Transformed Melanocytes", <u>Journal of Biological Chemistry</u> , 266(2):1147-1156 (1991)	
CN	KIM, et al., "Expression of a Thioredoxin-Related Protein-1 is Induced by Prostaglandin E ₂ ", <u>Int. J. Cancer</u> , 118:1670-1679 (2006)	
CO	KUZUMAKI, et al., "Eumelanin Biosynthesis is Regulated by Coordinate Expression of Tyrosinase and Tyrosinase-Related Protein-1 Genes", <u>Experimental Cell Research</u> , 207:33-40 (1993)	
CP	LEARNER, et al., "Biochemistry of Melanin Formation", <u>Physiol. Rev.</u> , 30(1):91-126 (1950)	
CQ	MACDONALD, "Expression of the Pancreatic Elastase I Gene in Transgenic Mice", <u>Hepatology</u> , 7(1):42S-51S (1987)	
CR	MASON, et al., "The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy", <u>Science</u> , 234(4782):1372-1378 (1986)	
CS	MCCURDY, "Enzyme Localization During Melanogenesis", <u>Journal of Cell Biology</u> , 48:220-228 (1969)	
CT	NIEKRASZ, et al., "The Pig as Organ Donor for Man", <u>Transplantation Proceedings</u> , 24(2):625-626 (1992)	
CU	OETTING, et al., "Mutations of the Human P Gene Associated with Type II Oculocutaneous Albinism (OCA2)", <u>Human Mutation</u> , 12(6):434 (1998)	
CV	ORLOW, "The Biogenesis of Melanosomes", in <u>The Pigmentary System: Physiology and Pathophysiology</u> , Norlund, et al., eds, Oxford University Press, Chapter 6, pp. 97-106 (1998)	
CW	ORLOW, et al., "Retinoic Acid is a Potent Inhibitor of Inducible Pigmentation in Murine and Hamster Melanoma Cell Lines", <u>Journal of Investigative Dermatology</u> , 64(4):461-464	
CX	ORNITZ, et al., "Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice", <u>Cold Spring Harb. Symp. Quant. Biol.</u> , 50:399-409 (1985)	
CY	PINKERT, et al., "An Albumin Enhancer Located 10 kb Upstream Functions Along with Its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice", <u>Genes & Development</u> , 1:268-276 (1987)	
CZ	Product Information Sigma: Composition of the Medium Ham's F10	
CA1	Product Information Sigma: Composition of the Medium MCDB-153	
CB1	<u>Remington's Pharmaceutical Sciences</u> , 18th Edition, Alfonso Gennaro, Editor, Mack Publishing Company, Easton, PA (1990)	
CC1	SAKAI, et al., "Modulation of Murine Melanocyte Function <i>in vitro</i> by Agouti Signal Protein", <u>EMBO Journal</u> , 16(12):3544-3552 (1997)	
CD1	SCHWARTZ, et al., <u>Surface Active Agents, Their Chemistry and Technology</u> , Interscience Publishers, Inc, New York, NY (1949)	
CE1	SEIJI, et al., "Subcellular Localization of Melanin Biosynthesis", <u>Ann. NY Acad. Sci.</u> , 100:497-533 (1963)	
CF1	SHANI, "Tissue-Specific Expression of Rat Myosin Light-Chain 2 Gene in Transgenic Mice", <u>Nature</u> , 314:283-286 (1985)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	09/827,428-Conf. #6098
				Filing Date	April 6, 2001
				First Named Inventor	Seth J. ORLOW
				Art Unit	1614
				Examiner Name	A. A. Lewis
				Attorney Docket Number	0071369.00162US3/PFI-016CIP
Sheet	3	of	3		

CG1	YOKOYAMA, et al., "Conserved Cysteine to Serine Mutation in Tyrosinase is Responsible for the Classical Albino Mutation in Laboratory Mice", Nucleic Acids Research, 18(24):7293-7298 (1990)	
-----	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--